OSTX OS Therapies Incorporated

-

OS Therapies Beat Consensus Estimates

Friday, August 14, 2026 · 12:00 AM ET

OS Therapies (OSTX) reported a loss of $0.20 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus estimate was a loss of $0.25 per share. The company beat consensus estimates by 20.00%.

OS Therapies Incorporated is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma and other solid tumors. The company's lead asset consists OST-HER2. OS Therapies Incorporated is based in NEW YORK.

Earnings Whisper Grade
Power Rating
Reported Earnings
($0.20)
Earnings Whisper®
Consensus Estimate
($0.25)
Earnings Surprise
Earnings Growth-5.3 %
Reported Revenue
Revenue Estimate
Revenue Surprise
Revenue Growth